Last reviewed · How we verify
NCT04343495
UV and Bluelight Dosimetry
trial testing Wearable Ultra Violet (UV) and blue-light sensors in Environmental Exposure. Withdrawn.
1 December 2023
Quick facts
| Lead sponsor | Northwestern University |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 July 2022 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 February 2024 |
Drugs / interventions tested
- Wearable Ultra Violet (UV) and blue-light sensors
Conditions studied
- Environmental Exposure — all drugs for Environmental Exposure →
Sponsor
Northwestern University
Who can join
18 and older, any sex, with Environmental Exposure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study to assess the efficacy of wearable Ultra Violet (UV) and blue-light sensors in measuring exposure to UV radiation and blue light in a variety of environments and activity settings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04343495
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Environmental Exposure
Currently open trials in the same condition.
- NCT07103356 — Table-Top Water Pitcher to Reduce Arsenic Exposure Among Well Users in New Hampshire · NA · recruiting
- NCT07514377 — JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China · active not recruiting
- NCT07313904 — Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis · recruiting
- NCT06529913 — Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases · NA · recruiting
- NCT07384676 — Environmental and Behavioral Factors in Infertility and ART Outcomes · recruiting
Other Northwestern University trials
Trials by the same sponsor.
- NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
- NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
- NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
- NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
- NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04343495 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwestern University
- Last refreshed: 29 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04343495.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing